Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1940–1943. doi: 10.1128/aac.41.9.1940

Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.

R A Bonomo 1, J R Knox 1, S D Rudin 1, D M Shlaes 1
PMCID: PMC164040  PMID: 9303389

Abstract

Amino acid changes that influence activity and resistance to beta-lactams and beta-lactamase inhibitors were explored by constructing the Gly238Ser and Met69Ile-Gly238Ser mutants of the OHIO-1 beta-lactamase, a class A enzyme of the SHV family. The Km values of cefotaxime and ceftazidime for OHIO-1 and Met69Ile beta-lactamases were > or = 500 microM. The Km of cefotaxime for the Gly238Ser beta-lactamase was 26 microM, and that of ceftazidime was 105 microM. The Km of cefotaxime for the Met69Ile-Gly238Ser beta-lactamase was 292 microM, and that of ceftazidime was 392 microM. For the beta-lactamase inhibitors clavulanate and sulbactam, the apparent Ki values for the Met69Ile-Gly238Ser enzyme were 0.03 and 0.15 microM, respectively. Relative Vmax values indicate that the Met69Ile-Gly238Ser mutant of the OHIO-1 beta-lactamase possesses cephalosporinase activity similar to that of the Gly238Ser mutant but diminished penicillinase activity. In an Escherichia coli DH5alpha strain that possesses a Met69Ile beta-lactamase of the OHIO-1 family, the added Gly238Ser mutation resulted in a phenotype with qualities that confer resistance to expanded-spectrum cephalosporins and, to a lesser extent, beta-lactamase inhibitors.

Full Text

The Full Text of this article is available as a PDF (189.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambler R. P., Coulson A. F., Frère J. M., Ghuysen J. M., Joris B., Forsman M., Levesque R. C., Tiraby G., Waley S. G. A standard numbering scheme for the class A beta-lactamases. Biochem J. 1991 May 15;276(Pt 1):269–270. doi: 10.1042/bj2760269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blazquez J., Baquero M. R., Canton R., Alos I., Baquero F. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Oct;37(10):2059–2063. doi: 10.1128/aac.37.10.2059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonomo R. A., Currie-McCumber C., Shlaes D. M. OHIO-1 beta-lactamase resistant to mechanism-based inactivators. FEMS Microbiol Lett. 1992 Apr 1;71(1):79–82. doi: 10.1016/0378-1097(92)90545-y. [DOI] [PubMed] [Google Scholar]
  4. Bonomo R. A., Dawes C. G., Knox J. R., Shlaes D. M. Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase. Biochim Biophys Acta. 1995 Feb 22;1247(1):113–120. doi: 10.1016/0167-4838(94)00187-l. [DOI] [PubMed] [Google Scholar]
  5. Bonomo R. A., Dawes C. G., Knox J. R., Shlaes D. M. beta-Lactamase mutations far from the active site influence inhibitor binding. Biochim Biophys Acta. 1995 Feb 22;1247(1):121–125. doi: 10.1016/0167-4838(94)00188-m. [DOI] [PubMed] [Google Scholar]
  6. Bush K., Jacoby G. A., Medeiros A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995 Jun;39(6):1211–1233. doi: 10.1128/aac.39.6.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Collatz E., Labia R., Gutmann L. Molecular evolution of ubiquitous beta-lactamases towards extended-spectrum enzymes active against newer beta-lactam antibiotics. Mol Microbiol. 1990 Oct;4(10):1615–1620. doi: 10.1111/j.1365-2958.1990.tb00537.x. [DOI] [PubMed] [Google Scholar]
  8. Henquell C., Chanal C., Sirot D., Labia R., Sirot J. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1995 Feb;39(2):427–430. doi: 10.1128/aac.39.2.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Huletsky A., Knox J. R., Levesque R. C. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling. J Biol Chem. 1993 Feb 15;268(5):3690–3697. [PubMed] [Google Scholar]
  10. Imtiaz U., Billings E. M., Knox J. R., Mobashery S. A structure-based analysis of the inhibition of class A beta-lactamases by sulbactam. Biochemistry. 1994 May 17;33(19):5728–5738. doi: 10.1021/bi00185a009. [DOI] [PubMed] [Google Scholar]
  11. Knox J. R. Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother. 1995 Dec;39(12):2593–2601. doi: 10.1128/aac.39.12.2593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kunkel T. A., Roberts J. D., Zakour R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
  13. Matagne A., Frère J. M. Contribution of mutant analysis to the understanding of enzyme catalysis: the case of class A beta-lactamases. Biochim Biophys Acta. 1995 Jan 19;1246(2):109–127. doi: 10.1016/0167-4838(94)00177-i. [DOI] [PubMed] [Google Scholar]
  14. McClary J. A., Witney F., Geisselsoder J. Efficient site-directed in vitro mutagenesis using phagemid vectors. Biotechniques. 1989 Mar;7(3):282–289. [PubMed] [Google Scholar]
  15. Raquet X., Lamotte-Brasseur J., Fonzé E., Goussard S., Courvalin P., Frère J. M. TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis. J Mol Biol. 1994 Dec 16;244(5):625–639. doi: 10.1006/jmbi.1994.1756. [DOI] [PubMed] [Google Scholar]
  16. Saves I., Burlet-Schiltz O., Swarén P., Lefèvre F., Masson J. M., Promé J. C., Samama J. P. The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the beta-lactamase resistance to clavulanic acid. J Biol Chem. 1995 Aug 4;270(31):18240–18245. doi: 10.1074/jbc.270.31.18240. [DOI] [PubMed] [Google Scholar]
  17. Shlaes D. M., Currie-McCumber C., Hull A., Behlau I., Kron M. OHIO-1 beta-lactamase is part of the SHV-1 family. Antimicrob Agents Chemother. 1990 Aug;34(8):1570–1576. doi: 10.1128/aac.34.8.1570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shlaes D. M., Currie-McCumber C. Mutations altering substrate specificity in OHIO-1, and SHV-1 family beta-lactamase. Biochem J. 1992 Jun 1;284(Pt 2):411–415. doi: 10.1042/bj2840411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sirot D., Recule C., Chaibi E. B., Bret L., Croize J., Chanal-Claris C., Labia R., Sirot J. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 1997 Jun;41(6):1322–1325. doi: 10.1128/aac.41.6.1322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stapleton P., Wu P. J., King A., Shannon K., French G., Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother. 1995 Nov;39(11):2478–2483. doi: 10.1128/aac.39.11.2478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thomson C. J., Amyes S. G. TRC-1: emergence of a clavulanic acid-resistant TEM beta-lactamase in a clinical strain. FEMS Microbiol Lett. 1992 Mar 1;70(2):113–117. doi: 10.1016/0378-1097(92)90669-f. [DOI] [PubMed] [Google Scholar]
  22. Vedel G., Belaaouaj A., Gilly L., Labia R., Philippon A., Névot P., Paul G. Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors. J Antimicrob Chemother. 1992 Oct;30(4):449–462. doi: 10.1093/jac/30.4.449. [DOI] [PubMed] [Google Scholar]
  23. Venkatachalam K. V., Huang W., LaRocco M., Palzkill T. Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J Biol Chem. 1994 Sep 23;269(38):23444–23450. [PubMed] [Google Scholar]
  24. Zafaralla G., Manavathu E. K., Lerner S. A., Mobashery S. Elucidation of the role of arginine-244 in the turnover processes of class A beta-lactamases. Biochemistry. 1992 Apr 21;31(15):3847–3852. doi: 10.1021/bi00130a016. [DOI] [PubMed] [Google Scholar]
  25. Zhou X. Y., Bordon F., Sirot D., Kitzis M. D., Gutmann L. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrob Agents Chemother. 1994 May;38(5):1085–1089. doi: 10.1128/aac.38.5.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES